CN102127508A - α-淀粉酶抑制剂产生菌及其筛选方法 - Google Patents
α-淀粉酶抑制剂产生菌及其筛选方法 Download PDFInfo
- Publication number
- CN102127508A CN102127508A CN 201010605912 CN201010605912A CN102127508A CN 102127508 A CN102127508 A CN 102127508A CN 201010605912 CN201010605912 CN 201010605912 CN 201010605912 A CN201010605912 A CN 201010605912A CN 102127508 A CN102127508 A CN 102127508A
- Authority
- CN
- China
- Prior art keywords
- alpha
- salivin
- amylase inhibitor
- water
- abs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 34
- 239000003392 amylase inhibitor Substances 0.000 title claims abstract description 32
- 101710171801 Alpha-amylase inhibitor Proteins 0.000 title claims abstract description 29
- 238000012216 screening Methods 0.000 title claims abstract description 27
- 229960002632 acarbose Drugs 0.000 claims abstract description 13
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical group O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims abstract description 12
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims abstract description 12
- 241000187712 Actinoplanes sp. Species 0.000 claims abstract description 4
- 238000004321 preservation Methods 0.000 claims abstract description 4
- 241000894006 Bacteria Species 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 238000012360 testing method Methods 0.000 claims description 24
- 239000000243 solution Substances 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- 239000007979 citrate buffer Substances 0.000 claims description 14
- 239000001488 sodium phosphate Substances 0.000 claims description 14
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 14
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 14
- 239000006228 supernatant Substances 0.000 claims description 13
- 229920001817 Agar Polymers 0.000 claims description 12
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 12
- 239000001888 Peptone Substances 0.000 claims description 12
- 108010080698 Peptones Proteins 0.000 claims description 12
- 229930006000 Sucrose Natural products 0.000 claims description 12
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 12
- 239000008272 agar Substances 0.000 claims description 12
- 235000019319 peptone Nutrition 0.000 claims description 12
- 239000005720 sucrose Substances 0.000 claims description 12
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 11
- 238000001816 cooling Methods 0.000 claims description 10
- 238000011081 inoculation Methods 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 9
- 229940088598 enzyme Drugs 0.000 claims description 9
- 239000008103 glucose Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 7
- 235000010469 Glycine max Nutrition 0.000 claims description 7
- 244000068988 Glycine max Species 0.000 claims description 7
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 7
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims description 7
- 235000011187 glycerol Nutrition 0.000 claims description 7
- 235000012204 lemonade/lime carbonate Nutrition 0.000 claims description 7
- 235000013923 monosodium glutamate Nutrition 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- 229940073490 sodium glutamate Drugs 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 238000004659 sterilization and disinfection Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 abstract description 13
- 230000008569 process Effects 0.000 abstract description 5
- 238000001514 detection method Methods 0.000 abstract description 3
- 238000012545 processing Methods 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 239000002609 medium Substances 0.000 description 25
- 235000011008 sodium phosphates Nutrition 0.000 description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- LWFUFLREGJMOIZ-UHFFFAOYSA-N 3,5-dinitrosalicylic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O LWFUFLREGJMOIZ-UHFFFAOYSA-N 0.000 description 3
- 239000004382 Amylase Substances 0.000 description 3
- 229940122816 Amylase inhibitor Drugs 0.000 description 3
- 102000013142 Amylases Human genes 0.000 description 3
- 108010065511 Amylases Proteins 0.000 description 3
- 235000019418 amylase Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 229940122069 Glycosidase inhibitor Drugs 0.000 description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 2
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229960000346 gliclazide Drugs 0.000 description 2
- 239000003316 glycosidase inhibitor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229960001110 miglitol Drugs 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 229960001729 voglibose Drugs 0.000 description 2
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- BOFRXDMCQRTGII-UHFFFAOYSA-N 619-08-9 Chemical class OC1=CC=C([N+]([O-])=O)C=C1Cl BOFRXDMCQRTGII-UHFFFAOYSA-N 0.000 description 1
- 241000187844 Actinoplanes Species 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 229940124036 Hydrolase inhibitor Drugs 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000004093 hydrolase inhibitor Substances 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000005468 ion implantation Methods 0.000 description 1
- 238000010884 ion-beam technique Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- -1 nitro amino Whitfield's ointment Chemical compound 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010605912 CN102127508B (zh) | 2010-12-25 | 2010-12-25 | α-淀粉酶抑制剂产生菌及其筛选方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010605912 CN102127508B (zh) | 2010-12-25 | 2010-12-25 | α-淀粉酶抑制剂产生菌及其筛选方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210224287.7A Division CN102864207B (zh) | 2010-12-25 | 2010-12-25 | 一种α-淀粉酶抑制剂产生菌的筛选方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102127508A true CN102127508A (zh) | 2011-07-20 |
CN102127508B CN102127508B (zh) | 2013-01-16 |
Family
ID=44265783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010605912 Active CN102127508B (zh) | 2010-12-25 | 2010-12-25 | α-淀粉酶抑制剂产生菌及其筛选方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102127508B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103114122A (zh) * | 2012-12-31 | 2013-05-22 | 浙江工业大学 | 利用游动放线菌制备反式-4-氨甲基-环己烷甲酸的方法 |
CN103207156A (zh) * | 2013-03-28 | 2013-07-17 | 山东博科生物产业有限公司 | 一种稳定的α-淀粉酶检测试剂及应用 |
CN103966206A (zh) * | 2013-01-25 | 2014-08-06 | 中国农业科学院植物保护研究所 | 一重组α-淀粉酶抑制剂蛋白质的制备及应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1262543A1 (en) * | 2000-03-10 | 2002-12-04 | Kabushiki Kaisha Yakult Honsha | Alpha-amylase activity inhibitors |
CN101139569A (zh) * | 2007-07-27 | 2008-03-12 | 南开大学 | 一株α-淀粉酶抑制剂生产菌及α-淀粉酶抑制剂的制备方法与应用 |
-
2010
- 2010-12-25 CN CN 201010605912 patent/CN102127508B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1262543A1 (en) * | 2000-03-10 | 2002-12-04 | Kabushiki Kaisha Yakult Honsha | Alpha-amylase activity inhibitors |
CN101139569A (zh) * | 2007-07-27 | 2008-03-12 | 南开大学 | 一株α-淀粉酶抑制剂生产菌及α-淀粉酶抑制剂的制备方法与应用 |
Non-Patent Citations (1)
Title |
---|
《食品科学》 20021231 吕凤霞等 alpha-淀粉酶抑制剂的研究进展 152-155 1-4 第23卷, 第3期 2 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103114122A (zh) * | 2012-12-31 | 2013-05-22 | 浙江工业大学 | 利用游动放线菌制备反式-4-氨甲基-环己烷甲酸的方法 |
CN103114122B (zh) * | 2012-12-31 | 2014-06-11 | 浙江工业大学 | 利用游动放线菌制备反式-4-氨甲基-环己烷甲酸的方法 |
CN103966206A (zh) * | 2013-01-25 | 2014-08-06 | 中国农业科学院植物保护研究所 | 一重组α-淀粉酶抑制剂蛋白质的制备及应用 |
CN103207156A (zh) * | 2013-03-28 | 2013-07-17 | 山东博科生物产业有限公司 | 一种稳定的α-淀粉酶检测试剂及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN102127508B (zh) | 2013-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tailliez et al. | Enhanced cellulose fermentation by an asporogenous and ethanol-tolerant mutant of Clostridium thermocellum | |
CN102796716B (zh) | 一种制备单宁酶的方法 | |
CN102127508B (zh) | α-淀粉酶抑制剂产生菌及其筛选方法 | |
CN104987316A (zh) | 一种海洋真菌来源的聚酮类化合物及其治疗ii型糖尿病的应用 | |
CN111218406B (zh) | 卷枝毛霉mf-8及其提高土茯苓中花旗松素含量的应用 | |
CN105838614B (zh) | 一种利用黑曲霉菌降解玉米赤霉烯酮的方法 | |
CN104911135B (zh) | 一种海藻糖合酶生产菌株及其应用 | |
CN104988125A (zh) | 高耐受性β-葡萄糖苷酶及其应用 | |
CN103937732B (zh) | 产中性纤维素酶菌株及选育方法和其生产纤维素酶的方法 | |
CN106167753A (zh) | 一种同步吸附‑共菌发酵法完全去除残次苹果酿造苹果酒中展青霉毒素的方法 | |
CN101215537A (zh) | 地衣芽孢杆菌及其应用 | |
CN102864207B (zh) | 一种α-淀粉酶抑制剂产生菌的筛选方法 | |
CN103880826A (zh) | 一种异苯并呋喃酮化合物及其制备方法和应用 | |
CN102433289B (zh) | 一株产瓜氨酸的菌株及用该菌株生物合成瓜氨酸的方法 | |
CN107125432B (zh) | 一种玉屏风药渣发酵的工艺方法 | |
CN108823118A (zh) | 一株能抑制α-葡萄糖苷酶活性的勒克菌及其应用 | |
CN103333872B (zh) | 一种制备β-葡萄糖醛酸苷酶粗酶制剂的方法 | |
CN109456898A (zh) | 一种球毛壳菌右旋糖酐酶的发酵制备及其应用 | |
CN104818235A (zh) | 一种路氏肠杆菌及其应用 | |
US20220370538A1 (en) | Method for extracting functional ingredients of mulberry leaves using enzymes | |
CN105368740A (zh) | 粘滑白蚁球菌TSB47、木聚糖酶TmXyn1及其编码基因和应用 | |
CN100582234C (zh) | 克列维醇在制备抗氧化剂的应用 | |
CN107056761A (zh) | 一种海洋真菌来源的九元环内酯衍生物及其制备方法和应用 | |
CN102559511B (zh) | 高产嗜温耐乙醇β-葡萄糖苷酶的肉座菌及其应用 | |
CN102732462B (zh) | 一株鲑鱼肾杆菌及其生产的酶 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHONGMEI HUADONG PHARMACEUTICAL CO. LTD., HANGZHOU Effective date: 20140103 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140103 Address after: Hangzhou City, Zhejiang province 310014 City Zhaohui District Six Patentee after: Zhejiang University of Technology Patentee after: Zhongmei Huadong Pharmaceutical Co., Ltd., Hangzhou Patentee after: Huadong Medicine Co., Ltd. Address before: Hangzhou City, Zhejiang province 310014 City Zhaohui District Six Patentee before: Zhejiang University of Technology |